SIMULATIONS PLUS INC (SLP)
US8292141053 - Common Stock
Simulations Plus Releases GastroPlus® X, The Next Generation PBPK/PBBM Modeling & Simulation Software
New AI Bot Predicts These 7 Stocks Will Mint Millionaires
A new AI model has identified these stocks as "millionaire makers." Here are the AI stock picks that could deliver life-changing returns.
YieldBoost Simulations Plus From 0.5% To 16.1% Using Options
Notable Thursday Option Activity: BYON, SLP, WIRE
Bullish Two Hundred Day Moving Average Cross - SLP
U.S. FDA Renews DILIsym® Software Licenses for 7th Year
SLP Stock Earnings: Simulations Plus Beats EPS, Beats Revenue for Q2 2024
SLP stock results show that Simulations Plus beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
SLP Stock Earnings: Simulations Plus Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Simulations Plus (NASDAQ:SLP) just reported results for the second quarter of 2...
Simulations Plus Reports Second Quarter Fiscal 2024 Financial Results
Simulations Plus Announces Second Quarter Fiscal Year 2024 Earnings and Conference Call Date
Simulations Plus to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
SLP Crosses Above Key Moving Average Level
Simulations Plus and the University of Bath Awarded New FDA Grant
Simulations Plus Extends Collaboration with Major Toxicology Research Agency
Simulations Plus Launches Corporate Development Initiative
SLP Makes Bullish Cross Above Critical Moving Average
Simulations Plus to Participate in Upcoming Healthcare Conferences
Simulations Plus Releases GastroPlus® Version 9.9
Simulations Plus Embarks on Collaboration with Northeastern University and The TIM Company Through New FDA Grant
Simulations Plus declares $0.06 dividend (NASDAQ:SLP)
Simulations Plus (SLP) declares $0.06/share quarterly dividend, in line with previous. Forward yield 0.56% Payable Feb. 5; for shareholders of record Jan. 29; e
SLP Stock Earnings: Simulations Plus Meets EPS, Beats Revenue for Q1 2024
SLP stock results show that Simulations Plus met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
SLP Stock Earnings: Simulations Plus Meets EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Simulations Plus (NASDAQ:SLP) just reported results for the first quarter of 20...
Simulations Plus Reports First Quarter Fiscal 2024 Financial Results
Simulations Plus Announces Leadership Appointments Supporting Commitment to Clients and Driving Growth
Simulations Plus Announces First Quarter Fiscal Year 2024 Earnings and Conference Call Date
Commit To Buy Simulations Plus At $30, Earn 5.6% Annualized Using Options
Simulations Plus (SLP) Shares Cross Above 200 DMA
KeyBanc sees opportunity in tech-enabled drug discovery stocks (NASDAQ:ABCL)
KeyBanc has initiated coverage of the tech-enabled drug discovery subsector, citing increasing demand for products that can help lower drug development costs. Read more here.